BMS Keeping ConvaTec, Cutting Zimmer: Matching Howmedica May Be Hard
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's exit from non-pharmaceutical businesses will not include the divestiture of ConvaTec. BMS is retaining the wound management business with the goal of reversing the division's recent sluggish sales results.
You may also be interested in...
Bristol-Myers Squibb Divests Imaging Agents, Considers Sale Of ConvaTec
Bristol-Myers Squibb is evaluating strategic alternatives for its ConvaTec ostomy and wound care device business following the divestiture of its imaging agent franchise, announced Dec. 17
Bristol-Myers Squibb Divests Imaging Agents, Considers Sale Of ConvaTec
Bristol-Myers Squibb is evaluating strategic alternatives for its ConvaTec ostomy and wound care device business following the divestiture of its imaging agent franchise, announced Dec. 17
Zimmer's NexGen Knees Help Lift Second-Quarter Revenues 13% To $294 Mil.
A 28% jump in U.S. sales of knee implants and a 26% increase in domestic artificial hip revenues helped propel Zimmer Holdings's second-quarter corporate revenues ahead 13% to $294.3 mil., the firm reported July 25.